Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Deferred Revenue (2022 - 2025)

Historic Current Deferred Revenue for BridgeBio Pharma (BBIO) over the last 4 years, with Q3 2025 value amounting to $9.1 million.

  • BridgeBio Pharma's Current Deferred Revenue fell 2280.18% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year decrease of 2280.18%. This contributed to the annual value of $14.6 million for FY2024, which is 13956.69% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Current Deferred Revenue is $9.1 million, which was down 2280.18% from $10.5 million recorded in Q2 2025.
  • BridgeBio Pharma's Current Deferred Revenue's 5-year high stood at $15.1 million during Q2 2024, with a 5-year trough of $6.1 million in Q4 2023.
  • Its 4-year average for Current Deferred Revenue is $9.7 million, with a median of $8.6 million in 2022.
  • Per our database at Business Quant, BridgeBio Pharma's Current Deferred Revenue soared by 14312.4% in 2024 and then plummeted by 3018.94% in 2025.
  • Over the past 4 years, BridgeBio Pharma's Current Deferred Revenue (Quarter) stood at $8.2 million in 2022, then decreased by 25.26% to $6.1 million in 2023, then surged by 139.57% to $14.6 million in 2024, then tumbled by 37.78% to $9.1 million in 2025.
  • Its Current Deferred Revenue stands at $9.1 million for Q3 2025, versus $10.5 million for Q2 2025 and $11.6 million for Q1 2025.